On May 5, 2026, Revvity, Inc. reported its financial results for Q1 2026, including a probable sale of its Immunodiagnostics business in China for up to $200 million, with expected closure in 2027.
AI Assistant
REVVITY INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.